Search Patents
  • Patent number: 6239101
    Abstract: Small, buffer soluble polypeptides having amino acid structures corresponding to residues 234-486, 310-486, and 407-486, of thrombomodulin and functionally equivalent analogs thereof inhibiting the clotting activity of thrombin and increasing protein C activation. The polypeptides can be coated onto the surface of articles adapted for contacting mammalian blood to render the surface non-thrombogenic. In pharmaceutical compositions, the polypeptides act as a natural anticoagulant.
    Type: Grant
    Filed: January 31, 1991
    Date of Patent: May 29, 2001
    Assignee: Oklahoma Medical Research Foundation
    Inventors: Charles T. Esmon, Naomi L. Esmon, Deborah J. Stearns, Shinichiro Kurosawa
  • Patent number: 5239056
    Abstract: A peptide fraction inducing the formation of antibodies which protect against the bovine leukemia virus (BLV), wherein it includes a peptide sequence which reproduces all or part of the sequence of the glycoprotein envelope gp51 fragment of the BLV virus which bears at least one of the epitopes (F, G, H) responsible for the biological activity of the virus. This fraction may be the fragment itself or a synthetic peptide. Application is made to the preparation or search for antibodies, to diagnosis and to the preparation of vaccines.
    Type: Grant
    Filed: February 5, 1992
    Date of Patent: August 24, 1993
    Assignee: Rhone Merieux
    Inventors: Daniel G. J. G. Portetellie, Arsene Leon G. Burny, Corine F. Dandoy, Helene S. C. Gras, nee Masse, Andre L. Tartar
  • Patent number: 5434245
    Abstract: There is provided a polypeptide having the following formula (I'), and which polypeptide is referred to as Glu-OC and a process for the preparation thereof.
    Type: Grant
    Filed: December 16, 1992
    Date of Patent: July 18, 1995
    Assignee: Takara Shuzo Co., Ltd.
    Inventors: Nobuto Koyama, Fusao Kimizuka, Ikunoshin Kato
  • Patent number: 5464823
    Abstract: Peptide-based compounds containing four invariant cysteine residues which have been oxidized to obtain two intramolecular disulfide bonds are useful as preservatives and in preventing, treating, or ameliorating viral or microbial infection in animals and plants. These compounds, in one embodiment, are of the formula:A.sub.1 -A.sub.2 -A.sub.3 -A.sub.4 -A.sub.5 -C-A.sub.7 -C-A.sub.9 -A.sub.10 -A.sub.11 -A.sub.12 -C-A.sub.14 -C-A.sub.16 -(A.sub.17 -A.sub.18)(1) (SEQ ID NO:4)and the N-terminal acylated, C-terminal amidated or esterified and the cystine-bridged forms thereofwherein A.sub.1, A.sub.9, A.sub.10 and A.sub.11 are basic amino acids;A.sub.2 and A.sub.3 are small amino acids;A.sub.5, A.sub.7, A.sub.12, A.sub.14 and A.sub.16 are hydrophobic amino acids; andA.sub.4 is a basic or a small amino acid;A.sub.17 is not present or, if present, is a small amino acid;A.sub.18 is not present or, if present, is a basic amino acid.
    Type: Grant
    Filed: July 26, 1993
    Date of Patent: November 7, 1995
    Assignee: The Regents of the University of California
    Inventors: Robert I. Lehrer, Vladimir N. Kokryakov, Sylvia S. L. Harwig
  • Patent number: 5032573
    Abstract: Microbially produced aprotinin and aprotinin homologs used for treating patients suffering from an excess release of pancreatic elastase, serum elastase or leukocyte elastase.
    Type: Grant
    Filed: October 2, 1989
    Date of Patent: July 16, 1991
    Assignee: Bayer Aktiengesellschaft
    Inventors: Ernst-August Auerswald, Werner Schroder, Eugen Schnabel, Wolfgang Bruns, Gerd Reinhardt, Michael Kotick
  • Patent number: 5095092
    Abstract: The invention relates to a process for the isolation and purification of hirudin from complex and salt-containing solutions by hydrophobic chromatography, using as stationary phase porous adsorber resins and as mobile phase organic solvents which are miscible with water.
    Type: Grant
    Filed: September 27, 1990
    Date of Patent: March 10, 1992
    Assignee: Hoechst Aktiengesellschaft
    Inventors: Werner Badziong, Peter Crause, Paul Habermann, Dominique Tripier
  • Patent number: 5326580
    Abstract: Disclosed herein is a protein sweetener that has been isolated from Pentadiplandra brazzeana Baillon. The sweetener is thermostable, lysine rich, and has a relative long lasting taste. Also disclosed is a recombinant host capable of producing the sweetener in large quantities. Compositions of this sweetener with other sweeteners are also disclosed.
    Type: Grant
    Filed: February 16, 1993
    Date of Patent: July 5, 1994
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Bengt G. Hellekant, Ding Ming
  • Patent number: 5478923
    Abstract: Single-chain analogs of the naturally occurring two-chain peptide monellin retain the sweetening properties of the natural protein and are stable under conditions which would otherwise destabilize the native peptide. A covalent linkage joins peptides corresponding to portions of the A and B chains of the naturally occurring protein.
    Type: Grant
    Filed: March 25, 1994
    Date of Patent: December 26, 1995
    Assignees: The Regents of the University of California, Lucky, Ltd.
    Inventors: Sung-Hou Kim, Joong M. Cho
  • Patent number: 5268358
    Abstract: Methods and compositions are provided for treating several acute disease states associated with smooth muscle cell proliferation as well as the chronic process of atherogenesis utilizing oligopeptides corresponding to regions of the PDGF receptor protein. The oligopeptides can be used to block PDGF binding and activation for numerous applications, and can serve as immunogens to raise receptor-specific antibodies.
    Type: Grant
    Filed: May 6, 1991
    Date of Patent: December 7, 1993
    Assignee: Cor Therapeutics, Inc.
    Inventor: Larry J. Fretto
  • Patent number: 5846733
    Abstract: The phosphorylated structural protein of molecular weight about 150 kd (pp 150) of human cytomegalovirus (HCMV) is highly immunogenic and is reliably recognised by human antisera. This protein can, after assignment and sequencing of the gene, be prepared, in whole or in immunogenic sections, by gene manipulation. Proteins of this type are suitable as reagents, for example in an ELISA, and as constituents of vaccines.
    Type: Grant
    Filed: April 28, 1995
    Date of Patent: December 8, 1998
    Assignee: Behring Diagnositcs GmbH
    Inventors: Gerhard Jahn, Birgit-Christine Scholl, Michael Broker, Michael Mach, Bernhard Fleckenstein, Bernd Traupe
  • Patent number: 5482928
    Abstract: Biocidal proteins isolated from Mirabilis have been characterized. The proteins show a wide range of antifungal activity and are active against gram-positive bacteria. DNA encoding the proteins has been isolated and incorporated into vectors. Plants transformed with this DNA have been produced. The proteins find commercial application as antifungal or antibacterial agents; transformed plants will show increased disease-resistance.
    Type: Grant
    Filed: December 20, 1993
    Date of Patent: January 9, 1996
    Assignee: Imperial Chemical Industries PLC
    Inventors: Miguel De Bolle, Willem F. Broekaert, Bruno P. A. Cammue, Sarah B. Rees, Jozef Vanderleyden
  • Patent number: 5118668
    Abstract: Peptides having essentially the sequence of bovine pancreatic trypsin inhibitor (aprotinin) wherein one or more of the amino acids at positions 15, 16, 17, 18, 34, 39 and 52 are replaced by any naturally occurring amino acid produced by recombinant DNA technology, process, expression vector and recominant host therefor and pharmaceutical use thereof. Such peptides being useful as therapeutic agents in diseases connected with the presence of excessive amounts of proteinases.
    Type: Grant
    Filed: July 20, 1988
    Date of Patent: June 2, 1992
    Assignee: Bayer Aktiengesellschaft
    Inventors: Ernst-August Auerswald, Wolfgang Bruns, Dietrich Horlein, Gerd Reinhardt, Eugen Schnabel, Werner Schroder
  • Patent number: 5422427
    Abstract: The present invention relates, in general, to pneumococcal fimbrial protein A. In particular, the present invention relates to a DNA segment encoding a pneumococcal fimbrial protein A gene; polypeptides encoded by said DNA segment; recombinant DNA molecules containing the DNA segment; cells containing the recombinant DNA molecule; a method of producing a pneumococcal fimbrial protein A polypeptide; antibodies specific to pneumococcal fimbrial protein A; and a method of measuring the amount of pneumococcal fimbrial protein A in a sample.
    Type: Grant
    Filed: September 17, 1991
    Date of Patent: June 6, 1995
    Assignee: The United States of America as represented by the United States Department of Health and Human Services
    Inventors: Harold Russell, Jacquelyn Sampson, Steven P. O'Connor
  • Patent number: 5432155
    Abstract: Substantially pure conotoxins are provided which inhibit synaptic transmissions at the neuromuscular junctions and which are useful both in vivo and in assays because they specifically target particular receptors, such as the acetylcholine receptor, and ion channels. The peptides are of such length that they can be made by chemical synthesis. They also may be made using recombinant DNA techniques, and the DNA encoding such conotoxins having pesticidal properties can be incorporated as plant defense genes into plant species of interest.
    Type: Grant
    Filed: June 29, 1993
    Date of Patent: July 11, 1995
    Assignees: The Salk Institute For Biological Studies, University of Utah Research Foundation
    Inventors: Baldomero M. Olivera, Jean E. F. Rivier, Lourdes J. Cruz, Fe Abogadie, Chris E. Hopkins, John Dykert, Josep L. Torres